Some of these patients have clinical features of vasculitis consistent with Churg-Strauss syndrome, a condition that is often treated with systemic corticosteroid therapy. JAMA 271 (1994): 1412-618. There have been reports of anaphylactic reactions in patients with severe milk protein allergy after inhalation of powder products containing lactose; therefore, patients with severe milk protein allergy should not take Advair Diskus.Advise patients who are at an increased risk for decreased BMD that the use of corticosteroids may pose an additional risk.Inform patients that orally inhaled corticosteroids, including fluticasone propionate, may cause a reduction in growth velocity when administered to pediatric patients. Booth H, Bish R, Walters J, Whitehead F, Walters EH "Salmeterol tachyphylaxis in steroid treated asthmatic subjects." Rinse your mouth with                  •nausea and vomiting            water without swallowing after use to help prevent this.In children with asthma, infections in the ear, nose, and throat are common. One subject (3%) who received Advair Diskus 250/50 had an abnormal response (peak serum cortisol <18 mcg/dL) after dosing, compared with 2 subjects (6%) who received placebo, 2 subjects (6%) who received fluticasone propionate 250 mcg, and no subjects who received salmeterol.In a repeat-dose, 3-way crossover trial, 1 inhalation twice daily of Advair Diskus 100/50, FLOVENT DISKUS 100 mcg (fluticasone propionate inhalation powder 100 mcg), or placebo was administered to 20 adult and adolescent subjects with asthma. Subjects receiving Advair Diskus 250/50 had significantly greater improvements in FEVBaseline PEF measurements were similar across treatments: Advair Diskus 500/50, 359 L/min; fluticasone propionate 500 mcg, 351 L/min; and concurrent therapy, 345 L/min. Conclusions cannot be drawn from this trial because of the large number of dropouts (>50%) before the end of the follow-up and the maldistribution of covariates among the treatment groups that can affect BMD.Fracture risk was estimated for the entire population of subjects with COPD in the survival trial (N = 6,184). Some side effects of fluticasone / salmeterol may occur that usually Check with your health care professional if any of the following side effects The most common events that occurred more frequently were nasopharyngitis, The incidence of pneumonia was higher in adult subjects with 1. Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Lancet 351 (1998): 773-8026. The inhaler is packaged in a plastic-coated, moisture-protective foil pouch (NDC 0173-0697-00). A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma." Fluticasone propionate is weakly and reversibly bound to erythrocytes and is not significantly bound to human transcortin.An in vitro study using human liver microsomes showed that salmeterol is extensively metabolized to α-hydroxysalmeterol (aliphatic oxidation) by CYP3A4. Thorax 51 (1996): 1100-432. Advair HFA comes in a canister that is used with an actuator inhaler device.Use Advair HFA at the same time each day. You may report side effects to FDA at 1-800-FDA-1088.Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Based on the available data, the concomitant administration of methylxanthines with Advair Diskus did not alter the observed adverse event profile.Following administration of Advair Diskus to healthy adult subjects, peak plasma concentrations of fluticasone propionate were achieved in 1 to 2 hours. No significant clastogenic effect was seen in cultured human peripheral lymphocytes in vitro or in the in vivo mouse micronucleus test.Fertility and reproductive performance were unaffected in male and female rats at subcutaneous doses up to 50 mcg/kg (approximately 0.5 times the MRHDID for adults on a mcg/mIn an 18-month carcinogenicity study in CD-mice, salmeterol at oral doses of 400 mcg/kg and above (approximately 20 times the MRHDID for adults and children based on comparison of the plasma AUCs) caused a dose-related increase in the incidence of smooth muscle hyperplasia, cystic glandular hyperplasia, leiomyomas of the uterus, and ovarian cysts.

Holliday SM, Faulds D, Sorkin EM "Inhaled fluticasone propionate. Acute symptoms should be treated with an inhaled, short-acting betaWhen beginning treatment with Advair Diskus, patients who have been taking oral or inhaled, short-acting betaAdvair Diskus should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing LABA, as an overdose may result. There were no asthma-related deaths or intubations. Some of the dosage forms listed on this page may not apply to the brand name Advair Diskus.. For the Consumer. A causal relationship between fluticasone propionate and these underlying conditions has not been established.Advair Diskus, like all medicines containing sympathomimetic amines, should be used with caution in patients with convulsive disorders or thyrotoxicosis and in those who are unusually responsive to sympathomimetic amines. Eur Respir J 7 (1994): 2089-9017. Safe to use : Advair contains fluticasone, a steroid, and salmeterol, a long acting bronchodialtor. Advair Diskus should be used for patients not adequately controlled on a long-term asthma control medication such as an inhaled corticosteroid (ICS) or whose disease warrants initiation of treatment with both an ICS and long-acting betaAdult and Adolescent Patients Aged 12 Years and OlderWhen choosing the starting dosage strength of Advair Diskus, consider the patients’ disease severity, based on their previous asthma therapy, including the ICS dosage, as well as the patients’ current control of asthma symptoms and risk of future exacerbation.Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to fluticasone propionate, salmeterol, or any of the excipients Use of LABA as monotherapy (without ICS) for asthma is associated with an increased risk of asthma-related death [see Salmeterol Multicenter Asthma Research Trial (SMART)].